How rival Reps are pitching to HCPs

GLP-1 drug powerhouses Eli Lilly and Novo Nordisk are evolving their commercial strategies, with a new report finding that both pharmas have broadened their messaging to HCPs in Australia to emphasise their blockbuster brands’ obesity-related comorbidity indications.

To see the whole article please log in.

Tiffany Walker

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here